S'abonner

Lactogenesis and breastfeeding after immediate vs delayed birth-hospitalization insertion of etonogestrel contraceptive implant: a noninferiority trial - 22/12/22

Doi : 10.1016/j.ajog.2022.08.012 
Andrea Henkel, MD, MS a, , Klaira Lerma, MPH a, Griselda Reyes, MD a, b, Hanna Gutow, BA a, Jonathan G. Shaw, MD, MS a, c, Kate A. Shaw, MD, MS a
a Department of Obstetrics and Gynecology, Stanford University School of Medicine, Family Planning Services and Research, Stanford, CA 
b School of Medicine, University of California, San Francisco, San Francisco, CA 
c Division of Primary Care and Population Health, Department of Medicine, Stanford University School of Medicine, Stanford, CA 

Corresponding author: Andrea Henkel, MD, MS.

Abstract

Background

Initiating a progestin-based contraceptive before the drop in progesterone required to start lactogenesis stage II could theoretically affect lactation. Previous studies have shown that initiating progestin-based contraception in the postnatal period before birth-hospitalization discharge has no detrimental effects on breastfeeding initiation or continuation compared with outpatient interval initiation. However, there are currently no breastfeeding data on the impact of initiating the etonogestrel contraceptive implant in the early postnatal period immediately in the delivery room.

Objective

This study examined the effect of delivery room vs delayed birth-hospitalization contraceptive etonogestrel implant insertion on breastfeeding outcomes.

Study Design

This was a noninferiority randomized controlled trial to determine if time to lactogenesis stage II (initiation of copious milk secretion) differs by timing of etonogestrel implant insertion during the birth-hospitalization. We randomly assigned pregnant people to insertion at 0 to 2 hours (delivery room) vs 24 to 48 hours (delayed) postdelivery. Participants intended to breastfeed, desired a contraceptive implant for postpartum contraception, were fluent in English or Spanish, and had no allergy or contraindication to the etonogestrel implant. We collected demographic information and breastfeeding intentions at enrollment. Onset of lactogenesis stage II was assessed daily using a validated tool. The noninferiority margin for the mean difference in time to lactogenesis stage II was defined as 12 hours in a per-protocol analysis. Additional electronic surveys collected data on breastfeeding and contraceptive continuation at 2 and 4 weeks, and 3, 6, and 12 months.

Results

We enrolled and randomized 95 participants; 77 participants were included in the modified intention-to-treat analysis (n=38 in the delivery room group and n=39 in the delayed group) after excluding 18 because of withdrawing consent, changing contraceptive or breastfeeding plans, or failing to provide primary outcome data. A total of 69 participants were included in the as-treated analysis (n=35 delivery room, n=34 delayed); 8 participants who received the etonogestrel implant outside the protocol windows were excluded, and 2 participants from the delivery room group received the etonogestrel implant at 24 to 48 hours and were analyzed with the delayed group. Participants were similar between groups in age, gestational age, and previous breastfeeding experience. Delivery room insertion was noninferior to delayed birth-hospitalization insertion in time to lactogenesis stage II (delivery room [mean±standard deviation], 65±25 hours; delayed, 73±61 hours; mean difference, −9 hours; 95% confidence interval, −27 to 10). Onset of lactogenesis stage II by postpartum day 3 was not significantly different between the groups. Lactation failure occurred in 5.5% (n=2) participants in the delayed group. Ongoing breastfeeding rates did not differ between the groups, with decreasing rates of any/exclusive breastfeeding over the first postpartum year. Most people continued to use the implant at 12 months, which did not differ by group.

Conclusion

Delivery room insertion of the contraceptive etonogestrel implant does not delay the onset of lactogenesis when compared with initiation later in the birth-hospitalization and therefore should be offered routinely as part of person-centered postpartum contraceptive counseling, regardless of breastfeeding intentions.

Le texte complet de cet article est disponible en PDF.

Key words : breastfeeding, etonogestrel contraceptive implant, immediate postpartum contraception, lactation, lactogenesis, progestin-only contraception


Plan


 The authors report no conflict of interest.
 This work was made possible with support from the Stanford Division of Family Planning Services and Research and through a grant to G.R. from the University of California, San Francisco School of Medicine Clinical and Translational Research (CTR) track of Pathways to Discovery.
 Clinical trials registration and data sharing:
1) Date of registration: August 15, 2016
2) Initial enrollment: October 28, 2016
3) ClinicalTrials.gov Identifier: NCT02866643
4) URL: NCT02866643
5) Data sharing:
A) Yes
B) Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
C) Study protocol
D) Beginning 9 months and ending 36 months following article publication.
E) Investigators whose proposed use of the data has been approved by an independent review committee (“learned intermediary”) identified for this purpose. For individual participant data meta-analysis. Proposals should be directed to ahenkel@stanford.edu. To gain access, data requestors will need to sign a data access agreement.
 Cite this article as: Henkel A, Lerma K, Reyes G, et al. Lactogenesis and breastfeeding after immediate vs delayed birth-hospitalization insertion of etonogestrel contraceptive implant: a noninferiority trial. Am J Obstet Gynecol 2023;228:55.e1-9.


© 2022  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 228 - N° 1

P. 55.e1-55.e9 - janvier 2023 Retour au numéro
Article précédent Article précédent
  • Placement of an intrauterine device within 48 hours after early medical abortion—a randomized controlled trial
  • Sara Hogmark, Karin Lichtenstein Liljeblad, Niklas Envall, Kristina Gemzell-Danielsson, Helena Kopp Kallner
| Article suivant Article suivant
  • Reoperation and pain-related outcomes after hysterectomy for endometriosis by oophorectomy status
  • Alicia J. Long, Paramdeep Kaur, Alexandra Lukey, Catherine Allaire, Janice S. Kwon, Aline Talhouk, Paul J. Yong, Gillian E. Hanley

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.